Eton Pharma Launches Nitisinone Capsules for Ultra- Rare Diseases

Eton Pharmaceuticals, an innovative pharmaceutical company focused on developing, selling and commercializing products to address the unmet needs of patients with rare diseases, includes nitisinone capsules for treating hereditary tyrosinemia type 1 (HT-1)—dietary inhibition of tyrosine and phenylalanine.Tyrosinemia type 1 is a rare disease that affects fewer than 500 patients in the United States.

"Eton is committed to serving patients and families affected by rare diseases. We are proud to provide nitisinone to hundreds of patients across the United States and provide patient and provider support services. We believe our commercial infrastructure and strong patient support services will help us capture a significant share of the estimated $50 million annual nitisinone market,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Nitisinone capsules are available through Optime Care, a specialist medicine that helps patients with rare diseases manage their conditions. Optime Care partners with Eton Pharmaceuticals to run the Eton Cares program. The Eton Cares program offers a $0 copay for all institutionally insured patients, including prescription fulfillment, insurance product research, educational assistance, and financial assistance to eligible patients.

Physicians who wish to prescribe nitisinone capsules and choose Optime Care as their medication can do so by phone or by dialing the patient order form at 866-318-2990.

Nitisinone is a medicine used to treat adults and children with a genetic disease called tyrosinemia type 1 (HT-1). Nitisinone should be taken with a diet that reduces tyrosine and phenylalanine.

Eton is an innovative pharmaceutical company focused on developing, selling and commercializing products to meet the unmet needs of patients with rare diseases. The company has four products approved for rare diseases: Alkindi Sprinkle, carglumic acid, betaine anhydrous and nitisinone.